entinostat has been researched along with Lymphoma, Non-Hodgkin in 2 studies
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with refractory solid tumors and lymphoid malignancies were treated with oral MS-275 on a once weekly schedule for 4 weeks of a 6-week cycle." | 2.73 | Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. ( Chen, A; Chung, EJ; Conley, B; Donovan, E; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, M; Hwang, K; Kalnitskiy, M; Kummar, S; Lee, MJ; Maynard, K; Melillo, G; Murgo, AJ; Ryan, QC; Trepel, JB; Zwiebel, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jóna, A | 1 |
| Khaskhely, N | 1 |
| Buglio, D | 1 |
| Shafer, JA | 1 |
| Derenzini, E | 1 |
| Bollard, CM | 1 |
| Medeiros, LJ | 1 |
| Illés, A | 1 |
| Ji, Y | 1 |
| Younes, A | 1 |
| Kummar, S | 1 |
| Gutierrez, M | 1 |
| Gardner, ER | 1 |
| Donovan, E | 1 |
| Hwang, K | 1 |
| Chung, EJ | 1 |
| Lee, MJ | 1 |
| Maynard, K | 1 |
| Kalnitskiy, M | 1 |
| Chen, A | 1 |
| Melillo, G | 1 |
| Ryan, QC | 1 |
| Conley, B | 1 |
| Figg, WD | 1 |
| Trepel, JB | 1 |
| Zwiebel, J | 1 |
| Doroshow, JH | 1 |
| Murgo, AJ | 1 |
1 trial available for entinostat and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Enzyme Inhibitors; Fem | 2007 |
1 other study available for entinostat and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids | 2011 |